课题基金 / 基金详情

Dipiperidines as a new class of anti-TB drug

Dipiperidines as a new class of anti-TB drug
二哌啶作为新型抗结核药物
批准号:
6791830
负责人:
MARINA N PROTOPOPOVA
金额:
$29.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-08-01 至 2005-07-31

项目摘要

项目成果

MARINA N PROTOPOPOVA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请的总体目的是表征一类新型结核病(TB)治疗药物,这些药物在结构上与任何现有抗TB药物无关。三年前,Sequella获得了一项挑战资助,用于合成和表征现有一线结核病药物乙胺丁醇类似物的组合文库。虽然我们确实确定了几种有前途的乙胺丁醇类似物,我们正在推进这项工作的结果(我们的第一个先导化合物是在临床前毒理学研究,为IND提交做准备),我们还确定了一类新的化合物,基本上与乙胺丁醇结构无关。这类化合物以前没有描述过,这类化合物的几个代表对M.体外培养结核病在本申请中,我们建议使用一种综合方法来表征这些活性化合物,然后将其开发和精制成具有治疗TB潜力的先导分子。简而言之,我们将使用组合化学来创建一个有针对性的类似物库,以改进我们以前成功使用这种方法的理想特性。化学、生物学和药理学数据将用于开发所选电极导线系列的预期特征;系列的细化将产生进一步表征和临床前开发的候选物。该过程和具体目标是高度迭代的,从后来的目标中吸取的经验教训将循环回到具体目标I,以帮助设计更活跃的化合物。
英文摘要
DESCRIPTION (provided by applicant): The overall aim of this application is to characterize a new class of drugs to treat tuberculosis (TB) that are structurally unrelated to any existing anti-TB drugs. Three years ago, Sequella received a Challenge grant to synthesize and characterize combinatorial libraries of analogues to ethambutol, an existing front-line tuberculosis drug. While we did identify several promising ethambutol analogues that we are taking forward as a result of this work (our first lead compound is in preclinical toxicology studies in preparation for an IND-submission), we also identified a new class of compounds that are essentially structurally unrelated to ethambutol. This class of compounds has not previously been described, and several representatives of this class have excellent activity against M. tuberculosis in vitro. In this application, we propose to use an integrated approach to characterize these active compounds, then develop and refine them into lead molecules that have potential for therapeutic usage in TB. Briefly, we will use combinatorial chemistry to create a targeted library of analogues around to improve upon the desirable characteristics, building on our previous success with this approach. Chemical, biological, and pharmacological data will be used to develop desired profiles of the selected lead series; refinement of the series will result in candidates for further characterization and preclinical development. The process and the specific aims are highly iterative, and lessons learned from later aims will be cycled back to Specific Aim I to assist in the design of more active compounds.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.bmcl.2011.07.015
发表时间: 2011-09-15
期刊: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
影响因子: 2.7
作者: [Bogatcheva, Elena, Hanrahan, Colleen, Nikonenko, Boris, de los Santos, Gladys, Reddy, Venkata, Chen, Ping, Barbosa, Francis, Einck, Leo, Nacy, Carol, Protopopova, Marina]
通讯作者: Protopopova, Marina
Targeting MtrAB of M. tuberculosis
  • 批准号:
    8124205
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2011
  • 负责人:
    MARINA N PROTOPOPOVA
  • 依托单位:
Targeting MtrAB of M. tuberculosis
  • 批准号:
    8233978
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2011
  • 负责人:
    MARINA N PROTOPOPOVA
  • 依托单位:
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection
  • 批准号:
    8248700
  • 项目类别:
  • 资助金额:
    $80.64万
  • 财政年份:
    2011
  • 负责人:
    MARINA N PROTOPOPOVA
  • 依托单位:
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection
  • 批准号:
    8444472
  • 项目类别:
  • 资助金额:
    $72.58万
  • 财政年份:
    2011
  • 负责人:
    MARINA N PROTOPOPOVA
  • 依托单位:
海外基金